首页> 外文期刊>Genetic testing and molecular biomarkers >A Novel Trl-Allelic Insertion/Deletion Polymorphism in the Promoter of p21~(Waf1/Cip1) and the Association with Gastric Cancer
【24h】

A Novel Trl-Allelic Insertion/Deletion Polymorphism in the Promoter of p21~(Waf1/Cip1) and the Association with Gastric Cancer

机译:p21〜(Waf1 / Cip1)启动子中一种新型的Trl等位基因插入/缺失多态性与胃癌的关系

获取原文
获取原文并翻译 | 示例
       

摘要

Aims: p21~(Waf1/Cip1) is a cyclin-dependent kinase inhibitor that is pivotal in arresting cellular growth in terminal cell differentiation and apoptosis. Thus, the existence of natural variants of p21~(Waf1/Cip1) could be linked to specific cancer. The purpose of this report was to identify a novel tri-allelic insertion/deletion (INDEL) polymorphism (rs4135235) involving a poly-T sequence in the promoter region of p21~(Waf1/Cip1) gene and to explore its role in gastric cancer (GC). Method: A total of unrelated 676 subjects (376 GC patients; 300 cancer-free controls) were enrolled in the study, and genomic DNA was obtained from each subject for genotyping. PCR-directed sequencing technique was used to detect the genotypes of the polymorphism. TA cloning was used to confirm the existence of three alleles. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by unconditional logistic regression analysis. Results: Six genotypes (9T/9T, 10T/10T, 11T/11T, 9T/10T, 10T/11T, and 9T/11T) and three alleles (9Ts, 10Ts, and 11Ts) were identified among all study subjects. GC cases were different from the control group with over-representation of 9T/11T heterozygotes (19.7% vs. 12.3%) and under-repre-sentation of 10T/10T homozygotes (18.4% vs. 20.7%). Compared with those carrying 10T/10T, individuals with 9T/11T increased the susceptibility for GC (OR=1.797,95%CI=1.065-3.031). Conclusion: Our findings confirmed the existence of a tri-allelic polymorphism in the promoter of p21~(Waf1/Cip1). It has also shown the heterozygous genotype 9T/11T to be a potential risk factor for GC in the Chinese population.
机译:目的:p21〜(Waf1 / Cip1)是一种依赖细胞周期蛋白的激酶抑制剂,在抑制终末细胞分化和凋亡中的细胞生长中起关键作用。因此,p21〜(Waf1 / Cip1)天然变异体的存在可能与特定的癌症有关。本报告旨在鉴定一种新的三等位基因插入/缺失(INDEL)多态性(rs4135235),其在p21〜(Waf1 / Cip1)基因的启动子区域中包含一个poly-T序列,并探讨其在胃癌中的作用(GC)。方法:共纳入无关的676名受试者(376名GC患者; 300名无癌对照),并从每名受试者中获得基因组DNA进行基因分型。用PCR指导的测序技术检测多态性的基因型。 TA克隆被用于确认三个等位基因的存在。通过无条件逻辑回归分析估计赔率(OR)和95%置信区间(CI)。结果:在所有研究对象中鉴定出6个基因型(9T / 9T,10T / 10T,11T / 11T,9T / 10T,10T / 11T和9T / 11T)和3个等位基因(9T,10T和11T)。 GC病例与对照组不同,9T / 11T杂合子的比例过高(19.7%对12.3%),而10T / 10T纯合子的表象表达不足(18.4%对20.7%)。与携带10T / 10T的人相比,患有9T / 11T的人增加了对GC的敏感性(OR = 1.797,95%CI = 1.065-3.031)。结论:我们的发现证实了p21〜(Waf1 / Cip1)启动子中存在一个三等位基因多态性。研究还表明,杂合子基因型9T / 11T是中国人群GC的潜在危险因素。

著录项

  • 来源
    《Genetic testing and molecular biomarkers》 |2014年第2期|112-116|共5页
  • 作者单位

    Key Laboratory of Reproduction and Heredity, Oncology Department of Cancer Hospital, General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China,Radiology Department of General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China;

    Key Laboratory of Reproduction and Heredity, Oncology Department of Cancer Hospital, General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China;

    Oncology Department of Cancer Hospital and Institute, General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China;

    Key Laboratory of Reproduction and Heredity, Oncology Department of Cancer Hospital, General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China;

    Surgical Laboratory of General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China;

    Oncology Department of Cancer Hospital and Institute, General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China;

    Surgical Laboratory of General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China;

    Key Laboratory of Reproduction and Heredity, Oncology Department of Cancer Hospital, General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China;

    Key Laboratory of Reproduction and Heredity, Oncology Department of Cancer Hospital, General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China;

    Oncology Department of Cancer Hospital and Institute, General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China,Surgical Laboratory of General Hospital Ningxia Medical University Yinchuan 750004 People's Republic of China;

    Oncology Department of Cancer Hospital and Institute, General Hospital, Ningxia Medical University, Yinchuan, People's Republic of China,Key Laboratory of Reproduction and Heredity Oncology Department of Cancer Hospital General Hospital, Ningxia Medical University Yinchuan 750004 People's Republic of China;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 13:16:31

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号